Background: The anti-cancer role of metformin has been reported in many different kinds of solid tumors, but how it affects non-small cell lung cancer (NSCLC) is currently elusive. The aim of this study was to investigate the influence of metformin treatment on diabetic NSCLC.
Methods: Two hundred fifty-five patients of diabetic NSCLC receiving therapy in our hospital from 2014 to 2016 were enrolled in our study. The information on clinical diagnosis, pathology, and prognosis as well as the influence of metformin in diabetic NSCLC were collected and assessed. Univariate and multivariate analytical techniques were applied to explore how metformin affect the survival of NSCLC.
Results: One hundred fifty of the 255 diabetic NSCLC patients took metformin. The median overall survival time (OST) and disease-free survival time (DFST) were significantly prolonged with metformin treatment compared to without metformin treatment (OST 25.0 vs 11.5 months, p = 0.005; DFST 15.6 vs 8.5 months, p = 0.010). Multivariate analysis indicated that metformin treatment could be used to predict the long-term outcome of diabetic NSCLC independently (HR = 0.588, 95% CI 0.466-0.895, p = 0.035).
Conclusion: Our study revealed that the metformin could help in improving the final outcome of NSCLC patients with diabetes in the long term and thus could be applied to treat NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859437 | PMC |
| http://dx.doi.org/10.1186/s12957-018-1362-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery and identification of semaphorin 4D as a bioindicator of high fracture incidence in type 2 diabetic mice with glucose control.
J Adv Res
March 2025
Department of Orthopaedics, Second Affiliated Hospital of Air Force Military Medical University, Xi'an 710038 Shaanxi, China. Electronic address:
Introduction: Bone fracture is increasing in patients with type 2 diabetes mellitus (T2DM) due to skeletal fragility. Most antidiabetics are expected to reduce the incidence of fracture in patients with T2DM, however the results are disappointing. Metformin and GLP-1 receptor agonists have a neutral or minor positive effect in reducing fractures.
View Article and Find Full Text PDFThe antitumor effects of metformin are potentially mediated through LPA receptor inhibition.
Diabetes Res Clin Pract
March 2025
Laboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation (IMCR), Gunma University, Maebashi 371-8512, Japan; Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan. Electronic address:
Aims: Although metformin has antitumor effects, the detailed mechanism of action, particularly with respect to the cellular responses mediated through G protein-coupled receptors (GPCRs), remains unclear.
Methods And Results: Here, we assayed a panel of 200 GPCRs in cells treated with metformin and reported that signaling through several receptors, including lysophosphatidic acid (LPA) receptors, was suppressed. Metformin significantly attenuated LPA-induced intracellular Ca mobilization in LPA receptor 1 (LPAR1)-, 2 (LPAR2)-, and 3 (LPAR3)-transfected rat hepatoma RH7777 cells.
Effect of Metformin Exposure in Gestational Diabetes Mellitus on Infant Mesenchymal Stem Cell Metabolism.
Am J Physiol Endocrinol Metab
March 2025
Department of Kinesiology, East Carolina University, Greenville, North Carolina, United States.
Offspring exposed to metformin treatment for gestational diabetes mellitus (GDM) experience altered growth patterns that increase the risk for developing cardiometabolic diseases later in life. The adaptive cellular mechanisms underlying these patterns remain unclear. Therefore, the objective of this study was to determine if chronic metformin exposure associated with GDM treatment elicits infant cellular metabolic adaptations.
View Article and Find Full Text PDFNeuroprotective Effects of Metformin in Stroke Patients: A Systematic Review and Meta-analysis of Cohort Studies.
Clin Neuropharmacol
March 2025
Department of Neurology, Firoozgar Hospital, School of Medicine, Iran University of Medical Science, Fasa, Iran.
Objectives: People with diabetes are 1.5 times more likely to experience stroke than those without diabetes, underlining the urgent need to address this issue. Metformin is often the initial medication chosen to manage diabetes mellitus (DM).
View Article and Find Full Text PDFAmniotic membrane hydrogel as novel injectable platform in combination with metformin for treatment of sciatic nerve injury.
J Appl Biomater Funct Mater
March 2025
Kerman Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Peripheral nerve tissue engineering is a field that uses cells, growth factors and biological scaffold material to provide a nutritional and physical support in the repair of nerve injuries. The specific properties of injectable human amniotic membrane-derived hydrogel including growth factors as well as anti-inflammatory and neuroprotective agents make it an ideal tool for nerve tissue repair, and metformin may also aid in nerve regeneration. The aim of this study was to investigate the effects of hydrogel derived from amniotic membrane (AM) along with metformin (MET) administration in the repair of sciatic nerve injury in male rats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!